Evidence map›Paper›PMID 39070506›Full record

ArticleCureus2024

Gemcitabine-Induced Thrombotic Microangiopathy in a Patient With Cholangiocarcinoma: An Atypical Case.

Vishwanath Anil, Ensaf Alhujaily, Deeksha Grover, Jolina P Santos, Ashok Kumar Kanugula, Moyosore Suleiman, Sonu Singh

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vishwanath AnilInternal Medicine, Wellstar Spalding Medical Center, Griffin, USA.
Ensaf AlhujailyInternal Medicine, Wellstar Spalding Medical Center, Griffin, USA.
Deeksha GroverInternal Medicine, Wellstar Spalding Medical Center, Griffin, USA.
Jolina P SantosNephrology, Wellstar Spalding Medical Center, Griffin, USA.
Ashok Kumar KanugulaInternal Medicine, Wellstar Spalding Medical Center, Griffin, USA.
Moyosore SuleimanHematology and Medical Oncology, Wellstar Spalding Medical Center, Griffin, USA.
Sonu SinghNephrology, Wellstar Spalding Medical Center, Griffin, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine-induced thrombotic microangiopathy (GITMA) is a rare but severe complication seen in cancer patients on gemcitabine therapy. This case report describes a 45-year-old female with metastatic cholangiocarcinoma on gemcitabine-capecitabine who developed acute kidney injury and hypertension without typical hematologic signs of thrombotic microangiopathy (TMA). Despite initial management targeting hypertensive urgency and acute kidney injury, renal function continued to decline and progressed to end-stage renal disease requiring hemodialysis. Laboratory tests revealed TMA features such as elevated lactate dehydrogenase (LDH), decreased haptoglobin, and schistocytes. Renal biopsy confirmed TMA with chronic features. This case highlights the challenge of diagnosing drug-induced TMA without typical hematologic findings.

Indexed as

chemotherapy-related toxicitycholangiocarcinomaend-stage renal disease (esrd)gemcitabine-induced thrombotic microangiopathymedication adverse effect

Identifiers

PMID39070506
PMCPMC11283843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.